Informing Decisions,
Improving Care
OncoMark Ltd, an Irish diagnostics company, today announced the results of two key studies on the clinical performance of its OncoMasTR test.
OncoMark Ltd, an Irish diagnostics company focused on the development of novel panels of cancer biomarkers to aid treatment decisions for cancer patients, today announced the appointment of Professor John Crown as the company’s Chief Medical Officer (CMO).
Presentations will highlight the clinical performance of the OncoMasTR test in the TransATAC and TAILORx tissue bank cohorts
OncoMark CEO Mr. Des O’Leary and OncoMark Business Development Manager Mr. Fergus Fleming are attending the Arab Health Exhibition and Congress at the Dubai International Convention and Exhibition Centre from the 29th January to the 1st February 2018.
OncoMark have initiated clinical validation of the OncoMasTR test using tumour samples from the TransATAC Tissue Resource.
OncoMark are pleased to announce the launch of their newly designed website www.oncomark.com. The website provides an enhanced user experience to our target audience to access information relating to OncoMark and the OncoMasTR test.
Study gives new hope of targeted treatment for triple negative breast cancer
Research led by Prof. William Gallagher, Director of BREAST-PREDICT and Chief Scientific Officer of OncoMark, has found a potential new approach to treating one of the most difficult-to-treat forms of breast cancer, which currently has limited treatment options.
OncoMark CEO Des O'Leary was awarded an Ireland's Champions of EU Research award from Enterprise Ireland at an event held in the Royal Hospital Kilmainham yesterday (Wednesday 28th June 2017).